BEGIN:VCALENDAR VERSION:2.0 PRODID:-//chikkutakku.com//RDFCal 1.0//EN X-WR-CALDESC:GoogleカレンダーやiCalendar形式情報を共有シェ アしましょう。近所のイベントから全国のイベントま で今日のイベント検索やスケジュールを決めるならち っくたっく X-WR-CALNAME:ちっくたっく X-WR-TIMEZONE:UTC BEGIN:VEVENT SUMMARY:CBE Seminar: Kannan Rangaramanujam\, Wayne State University\, “D evelopment and translation of cell-targeted systemic dendrimer precision n anomedicines" DTSTART;VALUE=DATE-TIME:20261013T153000Z DTEND;VALUE=DATE-TIME:20261013T163000Z UID:115556342780 DESCRIPTION:Sponsored by the Department of Chemical and Biomolecular Engin eeringHost: Ashish Kulkarniaakulkarni@umass.edu413-545-6892Kannan Rangaram anujamArnall Patz Distinguished Professor of Ophthalmology\, Center for Na nomedicine\, Johns Hopkins School of Medicine\, Baltimore\, Maryland\, USA  “Development and translation of cell-targeted systemic dendrimer preci sion nanomedicines”Tuesday\, October 13\, 2026\, 11:30 a.m.201 LGRT\, UM ass Amherst(Refreshments at 11:15 a.m.) Abstract:Dendrimers offer unique nanoscale attributes (e.g.\, surface group density) that can ‘tune’ th eir interactions with disease tissue and cells. Taking advantage of this\, we have developed dendrimers that target reactive microglia/macrophages\, injured’ neuronal cells\, adipocytes and more\, from systemic administr ation\, without a need for targeting ligands or antibodies. Through extens ive collaboration with physicians\, this has been validated in more than 5 5 animal models in six species\, and human tissue. Building on such select ive ‘disease biophysics’ uptake\, we have designed dendrimer-drug conj ugates which have shown significant promise in clinical trials\, addressin g decades-old medical challenges\, including overcoming the blood-brain ba rrier and developing systemic treatments for retinal disorders. These resu lts not only provide unique insights into the role of these key cells in d isease and repair but also offer opportunities for developing potent thera pies for unmet needs. Recent efforts to develop new applications in intrac ellular antibody delivery\, gene therapy\, and longevity will also be high lighted. Significant\, positive outcomes have been seen in six Phase 1 and two Phase 2 trials. OP-101@ (dendrimer-NAC conjugate) showed significant promise in Phase 2 trials for severe COVID-19 (>\;82% survival compared to 40% for standard of care) and was the only drug to address the neurolog ical consequences of COVID-19. Migaldendranib@ (dendrimer-sunitinib analog conjugate)\, a subcutaneous\, once-a-month\, cell-targeted therapy showed remarkable results in wet age-related macular degeneration and diabetic r etinopathy in Phase 2 trials (80% reduction in intravitreal Eylea@ injecti ons in BOTH eyes)\, with deep implications for early treatments for these large indications. The science of this biophysics-based cell-targeting\, a nd the remarkable promise of this approach in inflammatory\, brain\, pain\ , obesity\, mental health\, and retinal disorders will be discussed. Our a pproach suggests that novel solutions for long-standing problems may be at the exact opposite direction of conventional wisdom! Bio:Dr. Kannan Rang aramanujam is the Arnall Patz distinguished professor of ophthalmology and co-director of center for nanomedicine at the Wilmer Eye Institute at Joh ns Hopkins School of Medicine. He is a chemical engineer by training [PhD (Caltech)\; BE(Hons.) (BITS\, Pilani)]. His research interests are in the field of translational nanomedicine centered on novel approaches to target specific cells at the site of injury. His team has developed and extensiv ely validated the hydroxyl dendrimer and glucose dendrimer platforms throu gh Hopkins-wide collaborations in many animal models of ocular\, brain dis orders\, pain\, depression\, and cancer. These have the opportunity to add ress long-standing challenges in the field and will lead to medicines that are easy to administer (e.g.\, oral pills for AMD and diabetic retinopath y)\, have minimal side effects\, and affordable to large fractions of the world population. He is leading the translation of his research to the cli nic\, through start-ups and partnerships.  He is the co-founder of Ashvat tha Therapeutics Inc. and Samata Therapeutics (>\;$120M raised)\, and Av atar Precision Therapeutics – Johns Hopkins spinoffs that are translatin g some of his team’s patented dendrimer technologies to the clinic\, wit h three products that have completed Phase 2 trials. Dr. Rangaramanujam is an author of >\;190 patents (issued and pending\, licensed)\, >\;170 peer-reviewed publications\, and is supported by significant NIH and feder al funding. He has won several recognitions\, including fellowship of the American Institute of Medical and Biological Engineers (AIMBE)\, IAMBE\, C ontrolled Release Society\, and Distinguished Alumni Award from BITS (Pila ni). He is on the editorial boards of Biomaterials\, Advanced Drug Deliver y Reviews\, and Theranostics. https://gritdaily.com/dr-kannan-rangaramanuj am-translational-nanomedicine/ LOCATION:LGRT 201 END:VEVENT END:VCALENDAR